Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Clinical Trials (London, England)|March 23, 2023
Backfilling cohorts in phase I dose-escalation studiesHelen Barnett, Oliver Boix, Dimitris Kontos, et al.
Statistics in Biopharmaceutical Research|January 29, 2025
Joint TITE-CRM: A Design for Dose Finding Studies for Therapies with Late-Onset Safety and Activity OutcomesHelen Barnett, Oliver Boix, Dimitris Kontos, et al.
Statistics in Medicine|October 17, 2022
Dose finding studies for therapies with late-onset toxicities: A comparison study of designsHelen Barnett, Oliver Boix, Dimitris Kontos, et al.
Statistical Methods in Medical Research|December 5, 2025
Joint time-to-event partial order continual reassessment method and Joint time-to-event Bayesian logistic regression model: Statistical designs for dual agent phase I/II dose finding studies with late-onset toxicity and activity outcomesHelen Barnett, Oliver Boix, Dimitris Kontos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2012
A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumorsKlaus Mross, Annette Frost, Simone Steinbild, et al.
Cancer Chemotherapy and Pharmacology|August 19, 2015
A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancerRobin L Jones, Johanna C Bendell, David C Smith, et al.
Drug Discovery Today|January 23, 2026
The statistical software revolution in pharmaceutical development: challenges and opportunities in open sourceDaniel Sabanés Bové, Heidi Seibold, Anne-Laure Boulesteix, et al.
Cancers|December 15, 2019
Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived EfficacyAndreas Schneeweiss, Dagmar Hess, Markus Joerger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2022
First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical EfficacyJennifer R Diamond, Valentina Boni, Emerson Lim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2021
A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose EscalationFlorence Atrafi, Oliver Boix, Vivek Subbiah, et al.
Pageof 2